Home  Index  News  Cardiovascular side effects of cancer treatments

Cardiovascular side effects of cancer treatments

Cardiovascular side effects of cancer treatments
The cardiovascular side effects of cancer treatments remain a challenge in oncologic care. Patients with cancer and cancer survivors have an increased risk of adverse cardiovascular outcomes, including left ventricular (LV) dysfunction, heart failure (HF) and acute coronary events. The treatments most frequently associated with cardiovascular side effects include anthracyclines, monoclonal antibodies (mAbs) targeting the HER2 pathway, and small molecule tyrosine kinase inhibitors (TKIs), in particular vascular endothelial growth factor (VEGF)-signaling pathway (VSP) inhibitors. This review article focuses on the incidence and pathologic mechanisms of LV dysfunction observed with the most commonly implicated anticancer agents; summarises the existing clinical data on diagnosis, prevention and management of cardiac dysfunction related cancer therapeutics; and provides commentary on the cardiovascular risk associated with radiation, which may be used in conjunction with chemotherapy and biological therapies as part of multimodality cancer treatment.
Patients with cancer and cancer survivors have an increased risk of adverse cardiovascular outcomes, including left ventricular (LV) dysfunction, heart failure (HF) and acute coronary syndromes. These events are often a result of the cardiovascular toxicity of different cancer therapies and their synergism with cardiovascular risk factors and pre-existing cardiovascular disease. LV dysfunction and HF have been linked to many cancer therapeutics and incidence reports vary widely depending on the agent, definition, diagnostic methods and population.

Date: 10/29/2016
Source :


Darou Darman Pasargad Address :
No. 53, Amir Bldg, Baharan 1st St, Farahzadi Blvd, Saadat Abad, 1998939413, Tehran, Iran
Tel :
+98 21 88567958
Fax :
+98 21 88693778
© copyright 2016 Darou Darman Pasargad Co ALL RIGHTS RESERVED